EMA Grants PRIME Designation to Iopofosine I-131 for Waldens

The European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previously received at least 2 treatment regimens.

Related Keywords

United States , James Caruso , Cellectar Biosciences , European Union , European Medicines Agency Priority , European Medicines Agency , Cellectar Biosciences Inc , Priority Medicines , Fema , Prime Designation , Iopofosinei 131 , Waldenstrom Macroglobulinemia , Clr 131 , Clover 1 Trial , Fast Track Designation , Priority Medicines Designation ,